A critical hallmark of adaptive immune responses is the rapid and extensive expansion of lymph nodes. During this process, the complex internal structure of the organs is maintained revealing the existence of mechanisms able to balance lymph node integrity with structural flexibility. This article reviews the extensive architectural remodeling that occurs within lymph nodes during adaptive immune responses and how it is regulated by dendritic cells (DCs).
Summary
A critical hallmark of adaptive immune responses is the rapid and extensive expansion of lymph nodes. During this process, the complex internal structure of the organs is maintained revealing the existence of mechanisms able to balance lymph node integrity with structural flexibility. This article reviews the extensive architectural remodeling that occurs within lymph nodes during adaptive immune responses and how it is regulated by dendritic cells (DCs).
In particular we focus on previously unappreciated functions of DCs in coordinating remodeling of lymph node vasculature, expansion of the fibroblastic reticular network and maintenance of lymphoid stromal phenotypes. Our increased understanding of these processes indicates that DCs need to be viewed not only as key antigen-presenting cells for lymphocytes but also as broad-acting immune sentinels that convey signals to
Introduction
Lymph nodes act as pathogen filters, sites of encounter between antigenpresenting cells and lymphocytes and as environments for clonal expansion of antigen-specific T and B cells (1, 2) . Key to all these processes is the architecture of the lymph node, which is supported by a complex interconnecting scaffold of non-haematopoetic stromal cells, including specialised fibroblasts, lymphatic endothelial cells and blood endothelial cells (1, 3) . In addition to providing the physical infrastructure, stromal subsets help define different territories within lymph nodes. T cell areas contain fibroblastic reticular cells (FRCs) that account for 30-50% of total lymph node stroma and stretch throughout the paracortex forming a complex interconnected cellular network (1) (2) (3) . FRCs produce the CCR7 ligands, CCL19 and CCL21, that attract T cells and promote their migration, as well as IL-7, which acts as a T cell trophic signal (4, 5) . B cell follicles are supported by follicular dendritic cells (FDCs), a rarer stromal cell subset that produces CXCL13 along with growth factors such as BAFF necessary for the proliferation and maintenance of B cells (6) . Additionally present throughout the node are specialized blood vessels, termed high endothelial venules (HEVs) , that support the immigration of T and B cells from the bloodstream and respond to inflammatory stimuli to increase such traffic (7) . After entry into the lymph node via HEVs, lymphocytes utilise the stromal cell networks to migrate to their correct anatomical location and to meet antigen-presenting cells (2) .
Dendritic cells (DCs) are the classical antigen-presenting cells in lymphoid organs (8) . Some DCs are constitutively resident in those organs and differentiate locally from a blood-borne precursor (9, 10) . Other DCs are termed migratory and represent lymph-borne immigrants from peripheral tissues (11) . DC migration happens constitutively but is markedly accelerated after infection or inflammation (8, 11) . Within the lymph node, immigrant DCs bearing antigens acquired in the periphery, or resident DCs presenting antigens acquired from afferent lymph, become strategically positioned on the stromal network for scanning by naïve T cells (12) . T cells that encounter foreign antigen, together with appropriate co-signals, proliferate, differentiate and home to peripheral tissues in order to eliminate the challenge (8) .
One of the hallmarks of the immune reaction is massive lymph node expansion, with organ cellularity and physical size increasing 5-10 fold following immunisation or infection (1) It is becoming increasingly clear that DCs play a key role in this process by conveying key signals to stromal components that are required to initiate the remodeling of lymph node architecture and to support organ expansion. Thus, DCs not only deliver foreign antigens and promote activation and clonal expansion of T cells but also modify the lymph node environment to support that expansion. Here we specifically discuss the role of DCs in lymph node architecture and in its remodelling at the outset of immune responses.
DCs in antigen presentation to T cells
An adaptive immune response requires T cells to become stimulated in response to foreign antigens processed and presented by DCs. Sessile DCs present in tissues throughout the body continuously monitor their microenvironment for signs of tissue damage or infection. In response to these signs, DCs become motile and traffic to lymph nodes (8, 11, 13) . A key molecule upregulated during this transition is the chemokine receptor CCR7.
CCR7 has long been accepted as the critical receptor for entry of DCs into lymph nodes (14) but is now also known to be important for the mobilization of DCs within the tissues and for supporting their haptotactic migration towards afferent lymphatics at the start of their journey (15) . Whilst CCR7 undoubtedly controls the directional migration of DCs, our understanding of mechanisms controlling DC entry into lymph nodes has been recently expanded to include additional layers of complexity. The C-type lectin CLEC-2, whose expression on DCs is greatly increased following exposure to inflammatory stimuli (16) (17) (18) , has been shown to help promote the migratory behavior of the cells (16) .
CLEC-2 interacts with the glycoprotein ligand podoplanin (PDPN), also known as gp38, which is constitutively expressed on lymphatic endothelium and fibroblastic reticular cells (3, 19) , on which DCs crawl en route to and within the lymph node paracortex (20) . Triggering of CLEC-2 by PDPN promotes formation of actin-rich protrusions in DCs, via the activation of Vav and Rac1 (16) . These protrusions allow DCs to spread along stromal scaffolds and support DC motility (16) .
Another mechanism controlling lymph node entry of DCs operates at the level of the subcapsular sinus and involves the atypical chemokine receptor CCRL1 (21) . CCRL1 is expressed by lymphatic endothelial cells that line the celling but not the floor of the subcapsular sinus (21) . CCRL1 binds, sequesters and induces the degradation of CCL21 and CCL19, creating a gradient (21) . This allowing incoming antigen-laden DCs to keep moving towards the inner areas of the node an provides an elegant explanation as to how they reach the paracortex to find and prime naïve T cells.
Lymph arriving at lymph nodes via afferent lymphatic vessels flows beneath the capsule in the subcapsular sinus. Its ability to carry microbial debris and live organisms means that it can serve a rich source of antigens emanating from sites of infection. It had been suggested that DCs resident in the lymph node can acquire small soluble antigens arriving via the conduit network (see below) (22, 23) . More recently, it has been found that a subset of lymph noderesident DCs can also directly sample the contents of the subcapsular sinus and thereby acquire even large size pathogen material such as bacteria or viruses that drain from sites of infection via the afferent lymph (24) . Antigen acquisition by lymph node-resident DCs allows for rapid initiation of T cell responses to pathogens and complements antigen presentation by migratory DCs.
DCs in the filtering function of lymph nodes
In addition to acting as sites of antigen presentation, lymph nodes also act as filters for lymph draining from tissue. The inner sinus lining acts as a physical barrier between the lymph and the rest of the node. Migratory DCs and activated lymphocytes actively migrate through this barrier in order to reach the inner areas of the node. In contrast, soluble factors such as chemokines and cytokines that are sufficiently small (<70kDa) are permitted to flow through the lymph node confined within a network of conduits (25) . Conduits are essentially small interconnecting tubes constructed out of collagen and other basement membrane components (23, 25, 26) excreted by FRCs. These extracellular matrix components are then bundled and held together by the FRCs wrapping their cell bodies around them (19, 23) . Conduit size exclusion is controlled by a specialised lymphatic endothelial cell population that lines the celling and floor of the sinus and that expresses the glycoprotein PLVAP (27) . PLVAP allows these endothelial cells to forms diaphragms, effectively closing off the underlying conduit network to large molecules (27) .
There is also evidence that PLVAP + channels serve as a route for transmigrating leukocytes arriving via the afferent lymph as lymph nodes from mice lacking PLVAP become severely distorted and display an accumulation of activated B cells in enlarged follicles and a reduction in T cells (27) . Permitting large numbers of lymphocytes to enter lymph nodes following inflammation appears at odds with the ability of HEVs to maintain an effective barrier between the blood and the lymphoid tissue. One solution to these seemingly contradictory functions is again found in the crosstalk between FRCs and the endothelium (Fig. 1) . In inflamed lymph nodes, at the same time as numerous lymphocytes traffic through HEVs, platelets also leak from the blood into the perivascular space. Here, they immediately encounter FRCs that ensheath the endothelium. The FRCs in this space, similar to FRCs through the rest of the network, express high levels of PDPN that triggers CLEC-2, which is constitutively expressed at high levels on platelets (41) CLEC-2 signalling via the kinase Syk leads to the release of sphingosine-1-phosphate (S1P) from platelets, which acts on the endothelium to induce upregulation of VE-cadherin, a critical junctional protein (42) . The upregulation of VE-cadherin is sufficient to reinforce the endothelial cell-cell junctions and maintain the barrier function of the HEV (42), preventing further leakage of blood components into the tissue. In genetic models of ablation of either PDPN from FRCs or CLEC-2 from platelets, severe bleeding within the lymph nodes occurred, a defect which could be rescued by the transfusion of CLEC-2-sufficient platelets (42).
DCs in stretching of the FRC network.
In response to inflammation, HEV function is increased to facilitate ingress of lymphocytes from the blood while signals that permit lymphocyte egress from lymph nodes are downregulated, a process termed lymph node shutdown (43) . The net result is an increase in numbers of naïve lymphocytes accumulating in the reacting lymph node and this is what initially increases total lymph node cellularity before antigen-specific activation results in clonal proliferation of both B and T cells. As a result of both lymphocyte trapping and proliferation, lymph node cellularity rapidly increases, placing pressure and strain on the stromal architecture and forcing its remodeling (44, 45, 46) . It had been assumed that the enlargement of lymph nodes occurs through the synchronised and coordinated proliferation of stromal and lymphocytic components (3, 44) . This does seem to be true for the proliferation of blood endothelial cells, which begins very early in reactive lymph nodes (36) .
However, it is not the case for fibroblastic stroma. In fact, when stromal cell subsets and lymphocytes are enumerated over time following immunisation, a lag in the proliferation of FRCs can be observed (44, 45) . The length of this lag depends on the immune stimulus but can be as much as two days, during which time a marked increase in lymph node size has already taken place (44, 45) . How, then, does the lymph node accommodate increased cellularity in this early phase of an immune response without increasing numbers of FRCs? The FRC network is a highly contractile structure and in fact the size of the lymph node can be controlled via the tuning of contractility of FRCs, notably, by DCs (Fig. 2) .
Contractility in FRCs is driven by the activity of PDPN. We, and others have found that PDPN constitutively signals to drive actomyosin contractility without the requirement for engagement by an external ligand (45, 46) . In this state, the cytoplasmic tail of PDPN is serine phosphorylated (45, 47) and binds to ezrin/radixin/moesin proteins (45, 48) , connecting the plasma membrane to the underlying actin cytoskeleton. PDPN signaling also promotes RhoA/C activity, and activation of the RhoA/C effector Rho kinase (ROCK), which leads to phosphorylation of myosin light chain (MLC2) and the generation of contractile actin filaments (49) It is not yet clear which kinase is responsible for the phosphorylation and activation of PDPN and, furthermore, the direct connection between PDPN and RhoA activity remains to be fully characterised. Indeed, in one study, the ability of PDPN to drive contractility appeared independent of the cytoplasmic tail, raising the question of whether additional mechanisms exist to permit RhoA signaling (46) . Either way, this signaling and the associated contractile activity of PDPN is tempered by sequestration within cholesterol-rich lipid rafts, which uncouples PDPN from ezrin. This likely occurs through PDPN binding to inhibitory partners present in the membrane microdomain, including the hyaluronic acid receptor CD44, which itself can also drive contractility. Evidence suggests that when podoplanin is bound to CD44 both proteins become confined to cholesterolrich lipid rafts and this inhibits contractility induced by either one (50) .
The critical switch to drive PDPN into lipid rafts and thereby inhibit podoplanin-driven contractile activity is delivered by DCs in the form of CLEC-2. As already mentioned, CLEC-2 is upregulated on DCs following inflammation and helps promote DC motility (16) . But CLEC-2 is also a potent, short-acting inhibitor of PDPN (45, 46, 51) 
DCs in the expansion of the stromal network
Despite the remarkable flexibility of the stromal cell network, there comes a point, between 2-5 days after initiation of a response, where stretching is no longer sufficient to support lymph node expansion. Beyond this stage, an increased number of fibroblastic stromal cells are required. There are many potential cues to initiate proliferation of the existing FRC network. Perhaps proliferation is initiated as the physical limit of stromal cell length is maximised and the point at which the interconnected network is in danger of becoming detached and disconnected. Podoplanin activity may also play a role in controlling the proliferation of FRCs as FRCs from PDPN -/-mice proliferate more in culture that wildtype counterparts (46) . As PDPN signaling is inhibited by CLEC-2, it is reasonable to suppose that CLEC-2 + DCs not only provide the signal that causes FRC network stretching but also promote FRC proliferation. Consistent with that notion, increases in FRC number following LPS challenge in vivo are attenuated in CD11c Cre Clec1b fl/fl mice (46) . The number of CLEC-2 + DCs is at its peak during the acute phase of FRC stretching but it has also been reported that CLEC-2 can be cleaved and retain bioactivity in soluble form (53) so that there are potentially additional sources of CLEC-2 at later phases of LN expansion, including soluble CLEC-2 released from platelets. As FRCs relax their cytoskeleton and stretch to accommodate increased lymph node size, they increase in size (44, 45) . This change may be part of the set of cues that initiates the proliferation and expansion of the FRC network. FRCs may also respond directly to inflammatory stimuli prior to stretching priming them to proliferate, although it may also be possible that even a small change in physical tension at these early stages is the initiating factor for proliferation.
We know that fibroblastic stroma in the steady state can derive from a variety of sources (54) (55) (56) but the relative contribution of each of these sources to lymph node expansion during adaptive immune responses is unclear.
Proliferation of pre-existing FRCs can be documented by uptake of EdU or similar assays that identify proliferating cells (44) . Other data suggest a contribution from recruited percursors (57) . In particular, the adipose tissue of the fat pad, within which most lymph nodes are found embedded has been shown to act as a source of stromal precursors, both in development (58) and during lymph node expansion in adult mice (54) . In development, it has been described that a common mesenchymal precursor cell is able to give rise to both fibroblastic stroma in the developing lymph node and to adipocytes (59). There is some evidence that like FDCs, FRCs could also be derived via the conversion of another stromal subsets. Endosialin/TEM1 (CD248) is a fibroblast marker (65, 66) observed in inflammatory settings such as rheumatoid arthritis (67) . In resting lymph nodes CD248 expression is confined to the capsule but, following immunization, it is observed throughout the lymph node although, interestingly, shows little or no colocalisation with podoplanin (68). This lymph node-wide expression is relatively short-lived and disappears within 2-3 weeks of immunization. The identity and origin of the appearing CD248+ cells is still unclear, however, CD248 knockout mice exhibit significantly attenuated lymph node expansion at 5-7 days post immunization (68). CD248 expression is regulated by hypoxia (69) and in vitro at least has significant effects to promote proliferation and motility of mesenchymal cells (65, 68) . CD248+ cells might be fibroblasts from the There are likely to be several others and their elucidation will help our understanding of a process that is emerging to be just as critical to immunity as the delivery of antigen and the trafficking of leucocytes.
